Hunter Associates Investment Management LLC raised its position in shares of Pfizer Inc. (NYSE:PFE) by 27.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 197,438 shares of the biopharmaceutical company’s stock after buying an additional 42,825 shares during the period. Pfizer comprises approximately 2.7% of Hunter Associates Investment Management LLC’s holdings, making the stock its 7th largest position. Hunter Associates Investment Management LLC’s holdings in Pfizer were worth $6,413,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of PFE. Bank of The West boosted its stake in Pfizer by 28.0% in the third quarter. Bank of The West now owns 157,475 shares of the biopharmaceutical company’s stock worth $5,334,000 after buying an additional 34,415 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its stake in Pfizer by 24.5% in the third quarter. Oregon Public Employees Retirement Fund now owns 1,427,125 shares of the biopharmaceutical company’s stock worth $48,337,000 after buying an additional 280,987 shares during the last quarter. State of Alaska Department of Revenue boosted its stake in Pfizer by 31.1% in the third quarter. State of Alaska Department of Revenue now owns 487,552 shares of the biopharmaceutical company’s stock worth $16,512,000 after buying an additional 115,665 shares during the last quarter. Fisher Asset Management LLC boosted its stake in Pfizer by 0.4% in the third quarter. Fisher Asset Management LLC now owns 31,836,368 shares of the biopharmaceutical company’s stock worth $1,078,298,000 after buying an additional 111,838 shares during the last quarter. Finally, Stratos Wealth Partners LTD. boosted its stake in Pfizer by 6.9% in the third quarter. Stratos Wealth Partners LTD. now owns 132,431 shares of the biopharmaceutical company’s stock worth $4,485,000 after buying an additional 8,524 shares during the last quarter. Institutional investors and hedge funds own 69.53% of the company’s stock.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) opened at 34.38 on Tuesday. The company has a market capitalization of $204.63 billion, a price-to-earnings ratio of 29.31 and a beta of 0.94. Pfizer Inc. has a 1-year low of $29.17 and a 1-year high of $37.39. The stock has a 50 day moving average price of $33.34 and a 200-day moving average price of $32.84.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $0.47 EPS for the quarter, missing the Zacks’ consensus estimate of $0.50 by $0.03. Pfizer had a net margin of 13.50% and a return on equity of 23.18%. The firm earned $13.60 billion during the quarter, compared to the consensus estimate of $13.64 billion. During the same quarter in the prior year, the company earned $0.53 EPS. Pfizer’s quarterly revenue was down 3.0% on a year-over-year basis. Equities analysts predict that Pfizer Inc. will post $2.55 earnings per share for the current year.

Your IP Address:

A number of research firms recently issued reports on PFE. Piper Jaffray Companies set a $53.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Saturday, January 21st. BMO Capital Markets reissued a “hold” rating and set a $33.00 price objective on shares of Pfizer in a research report on Tuesday. Barclays PLC raised Pfizer from an “equal weight” rating to an “overweight” rating and set a $38.00 price objective for the company in a research report on Tuesday, November 29th. Vetr cut Pfizer from a “buy” rating to a “hold” rating and set a $33.68 price objective for the company. in a research report on Monday, March 13th. Finally, Credit Suisse Group AG set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Monday, March 13th. Thirteen research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $37.32.

In other Pfizer news, insider Rady A. Johnson sold 4,500 shares of the stock in a transaction dated Friday, March 10th. The stock was sold at an average price of $34.19, for a total transaction of $153,855.00. Following the completion of the transaction, the insider now owns 54,963 shares in the company, valued at approximately $1,879,184.97. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Mikael Dolsten sold 30,970 shares of the stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $34.51, for a total value of $1,068,774.70. Following the transaction, the insider now owns 64,719 shares of the company’s stock, valued at approximately $2,233,452.69. The disclosure for this sale can be found here. In the last quarter, insiders have sold 71,470 shares of company stock valued at $2,449,150. Corporate insiders own 0.07% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company’s segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products.

5 Day Chart for NYSE:PFE

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.